Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

NCT03618784 PHASE1, PHASE2 COMPLETED

Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis

Details

Lead sponsor	Kang Stem Biotech Co., Ltd.
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	33
Start date	Wed Jul 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Rheumatoid Arthritis

Interventions

• FURESTEM-RA Inj
• sterile saline

Countries

South Korea